Seven Key Products Are Projected to Generate $1 Billion in Sales in 5 Years
LAVAL, Quebec, Jan. 9, 2018 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX)
("Valeant" or the "Company") announced today it has published the
presentation that Joseph C. Papa,
chairman and chief executive officer, is scheduled to present at
the 36th Annual J.P. Morgan Healthcare Conference in
San Francisco, tomorrow,
Wednesday, Jan. 10, 2018, at
10:30 a.m. PST (1:30 p.m. EST).
The presentation provides an overview of the Company's recent
performance and accomplishments in its transformation and offers
insight into future catalysts, including seven key products that
have been recently approved or are filed with the U.S. Food and
Drug Administration. We believe these products will generate
approximately $1 billion in expected
annualized revenues at peak sales over the next five years.
The presentation is available on the Investor Relations page of
the Valeant web site at:
http://ir.valeant.com/events-and-presentations/2018.
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded
generics. More information about Valeant can be found at
www.valeant.com.
Forward-looking Statements
This news release may
contain forward-looking statements which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in the Company's most
recent annual or quarterly report and detailed from time to time in
Valeant's other filings with the Securities and Exchange Commission
and the Canadian Securities Administrators, which factors are
incorporated herein by reference. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of
the date hereof. Valeant undertakes no obligation to update any of
these forward-looking statements to reflect events or circumstances
after the date of this news release or to reflect actual outcomes,
unless required by law.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@valeant.com
|
lainie.keller@valeant.com
|
(514)
856-3855
|
(908)
927-0617
|
(877) 281-6642 (toll
free)
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/valeant-provides-company-update-at-the-36th-annual-jp-morgan-healthcare-conference-300579346.html
SOURCE Valeant Pharmaceuticals International, Inc.